A bill to amend the Internal Revenue Code of 1986 to deny tax benefits for research conducted by pharmaceutical companies where United States consumers pay higher prices for the products of that research than consumers in certain other countries
Contributors: United States. Congress. House. Committee on Ways and Means
Publisher: U.S. G.P.O.
Published: 2000
Place of publication: Washington, D.C
Language: eng
Subjects: Drugs; Research; Law and legislation; Pharmaceutical industry; Taxation; International business enterprises; Research and development tax credit; Prescription pricing
Other titles: Prescription Price Equity Act of 2000.; 106th Congress, 2d Session, H.R. 3665 in the House of Representatives.; To amend the Internal Revenue Code of 1986 to deny tax benefits for research conducted by pharmaceutical companies where United States consumers pay higher prices for the products of that research than consumers in certain other countries.
Notes: Caption title.

Introduced Feb. 15, 2000; referred to the Committee on Ways and Means.